Drug Pricing
340B
It’s Time For Congress To Get 340B Out Of Its Blind Spot
That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B. Read the full article at Forbes
Commentary
Trump Puts Drug Pricing Program Fraudsters on Notice
The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans. One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market. ...
Commentary
Germany Wants Cheaper Drugs—And Americans To Pay The Difference
What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually. The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines. ...
Commentary
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...
Commentary
Don’t penalize patients for shopping smart on drugs — reward them
Patients shouldn’t be penalized for finding a better deal on their prescriptions. Too often, they are. Those who pay out of pocket for medications — often at lower prices through direct-to-consumer platforms — typically receive no credit toward their health plan’s annual deductible. Higher-priced drugs purchased through an insurer’s preferred ...
Blog
The FTC Is Settling for Lower Drug Prices
The FTC alleged that Express Scripts “artificially inflated the list price of insulin drugs by using anticompetitive and unfair rebating practices, and impaired patients’ access to lower list price products, ultimately shifting the cost of high insulin list prices to vulnerable patients.” This is a big win – and not just for ...
Commentary
The Real Profiteers in Healthcare Aren’t Drugmakers
Pressure is building on Capitol Hill for Congress to codify President Trump’s “most favored nation” drug-pricing initiative into law. The administration has already struck deals with more than a dozen drugmakers to sell medicines to Medicaid, the federal-state health plan for low-income individuals and the disabled, at the lowest prices ...
Commentary
Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire
President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Commentary
Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing
President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
Commentary
In the rush to hold insurers to account, don’t forget about hospitals
When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.
It’s Time For Congress To Get 340B Out Of Its Blind Spot
That should alarm anyone concerned about rising healthcare costs, misuse of taxpayer dollars, financial burdens on employers, or the integrity of our nation’s safety net. Congress must stop ignoring this problem and inject some badly needed transparency into 340B. Read the full article at Forbes
Trump Puts Drug Pricing Program Fraudsters on Notice
The Trump administration is ramping up its fight against waste, fraud, and abuse in healthcare. And that effort could help make care more affordable for millions of Americans. One of its latest targets is the 340B Drug Pricing Program, a little-known federal initiative that has warped the prescription drug market. ...
Germany Wants Cheaper Drugs—And Americans To Pay The Difference
What does a new healthcare reform effort in Germany have to do with American patients? Quite a lot, actually. The German government is looking to cut healthcare spending by tens of billions of euros. To that end, it is pushing pharmaceutical companies to accept significantly lower prices for new medicines. ...
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...
Don’t penalize patients for shopping smart on drugs — reward them
Patients shouldn’t be penalized for finding a better deal on their prescriptions. Too often, they are. Those who pay out of pocket for medications — often at lower prices through direct-to-consumer platforms — typically receive no credit toward their health plan’s annual deductible. Higher-priced drugs purchased through an insurer’s preferred ...
The FTC Is Settling for Lower Drug Prices
The FTC alleged that Express Scripts “artificially inflated the list price of insulin drugs by using anticompetitive and unfair rebating practices, and impaired patients’ access to lower list price products, ultimately shifting the cost of high insulin list prices to vulnerable patients.” This is a big win – and not just for ...
The Real Profiteers in Healthcare Aren’t Drugmakers
Pressure is building on Capitol Hill for Congress to codify President Trump’s “most favored nation” drug-pricing initiative into law. The administration has already struck deals with more than a dozen drugmakers to sell medicines to Medicaid, the federal-state health plan for low-income individuals and the disabled, at the lowest prices ...
Trump’s Plan To Peg Drug Prices to Foreign Countries Could Backfire
President Trump famously quipped during his run for a second term that he had “concepts of a plan” to fix health care. That plan finally came together in January — and congressional Republicans are eager to codify its concepts into law. Most of Mr. Trump’s “Great Healthcare Plan” is promising. ...
Most-Favored-Nation Pricing Would Import Europe’s Drug Rationing
President Trump’s State of the Union address featured several promising healthcare ideas. Expanding access to patient-owned health savings accounts and routing federal subsidies through them, rather than through insurance companies, would unleash competition by empowering consumers to spend their healthcare dollars as they see fit. So would stronger price transparency ...
In the rush to hold insurers to account, don’t forget about hospitals
When asked to account for the skyrocketing cost of health coverage before two House committees last Thursday, the chief executives of five of America’s largest health insurance companies pointed fingers. Don’t look at us, they said. Look at hospitals and drugmakers. Read the op-ed here.